NASDAQ:SRTS - Sensus Healthcare Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.52 -0.22 (-2.84 %) (As of 02/15/2019 04:00 PM ET)Previous Close$7.52Today's Range$7.30 - $8.6352-Week Range$5.00 - $8.88Volume77,072 shsAverage Volume50,412 shsMarket Capitalization$120.96 millionP/E Ratio-26.86Dividend YieldN/ABeta-0.43 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides Sentinel service program, which offers its customers protection for their SRT-100 and SRT-100 Vision systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida. Receive SRTS News and Ratings via Email Sign-up to receive the latest news and ratings for SRTS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRTS Previous Symbol CUSIPN/A Webwww.sensushealthcare.com Phone561-922-5808Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.01Price-To-Earnings Trailing P/E Ratio-26.86 Forward P/E Ratio-41.78 P/E GrowthN/A Sales & Book Value Annual Sales$20.59 million Price / Sales5.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book8.64Profitability EPS (Most Recent Fiscal Year)($0.28) Net Income$-3,710,000.00 Net Margins-10.21% Return on Equity-16.98% Return on Assets-11.03%Miscellaneous Employees45 Outstanding Shares16,085,000Market Cap$120.96 million OptionableNot Optionable Sensus Healthcare (NASDAQ:SRTS) Frequently Asked Questions What is Sensus Healthcare's stock symbol? Sensus Healthcare trades on the NASDAQ under the ticker symbol "SRTS." How were Sensus Healthcare's earnings last quarter? Sensus Healthcare Inc (NASDAQ:SRTS) announced its earnings results on Thursday, February, 14th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. The firm earned $8.08 million during the quarter, compared to analyst estimates of $7.33 million. Sensus Healthcare had a negative return on equity of 16.98% and a negative net margin of 10.21%. View Sensus Healthcare's Earnings History. When is Sensus Healthcare's next earnings date? Sensus Healthcare is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Sensus Healthcare. What price target have analysts set for SRTS? 6 Wall Street analysts have issued 1-year target prices for Sensus Healthcare's shares. Their forecasts range from $5.00 to $14.00. On average, they expect Sensus Healthcare's share price to reach $10.6667 in the next twelve months. This suggests a possible upside of 41.8% from the stock's current price. View Analyst Price Targets for Sensus Healthcare. What is the consensus analysts' recommendation for Sensus Healthcare? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sensus Healthcare in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sensus Healthcare. Has Sensus Healthcare been receiving favorable news coverage? Press coverage about SRTS stock has trended neutral recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sensus Healthcare earned a news impact score of 0.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. Who are some of Sensus Healthcare's key competitors? Some companies that are related to Sensus Healthcare include Orthopediatrics (KIDS), SI-Bone (SIBN), Axonics Modulation Technologies (AXNX), Accuray (ARAY), Pulse Biosciences (PLSE), GenMark Diagnostics (GNMK), Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), MiMedx Group (MDXG), Neuronetics (STIM), Iradimed (IRMD), SeaSpine (SPNE), Vapotherm (VAPO), Apyx Medical (APYX) and Westaim (WEDXF). Who are Sensus Healthcare's key executives? Sensus Healthcare's management team includes the folowing people: Mr. Joseph C. Sardano, Chairman, CEO & Pres (Age 66)Mr. Arthur R. Levine, Chief Financial Officer (Age 61)Mr. Kalman Fishman, COO & CTO (Age 48)Mr. Michael Sardano, Gen. Counsel, Corp. Sec. and Director of Governance & Regulatory (Age 31)Mr. Richard Golin, Exec. VP of International (Age 65) When did Sensus Healthcare IPO? (SRTS) raised $20 million in an IPO on Wednesday, March 30th 2016. The company issued 1,800,000 shares at a price of $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company acted as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager. Who are Sensus Healthcare's major shareholders? Sensus Healthcare's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.28%), BlackRock Inc. (0.16%) and Northern Trust Corp (0.07%). Company insiders that own Sensus Healthcare stock include Arthur Levine, Joseph C Sardano, Kalman Fishman, Richard Golin and Stephen Brad Cohen. View Institutional Ownership Trends for Sensus Healthcare. Which major investors are buying Sensus Healthcare stock? SRTS stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Northern Trust Corp and BlackRock Inc.. View Insider Buying and Selling for Sensus Healthcare. How do I buy shares of Sensus Healthcare? Shares of SRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sensus Healthcare's stock price today? One share of SRTS stock can currently be purchased for approximately $7.52. How big of a company is Sensus Healthcare? Sensus Healthcare has a market capitalization of $120.96 million and generates $20.59 million in revenue each year. The company earns $-3,710,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. Sensus Healthcare employs 45 workers across the globe. What is Sensus Healthcare's official website? The official website for Sensus Healthcare is http://www.sensushealthcare.com. How can I contact Sensus Healthcare? Sensus Healthcare's mailing address is 851 BROKEN SOUND PARKWAY NW SUITE 215, BOCA RATON FL, 33487. The company can be reached via phone at 561-922-5808 or via email at [email protected] MarketBeat Community Rating for Sensus Healthcare (NASDAQ SRTS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 83 (Vote Outperform)Underperform Votes: 76 (Vote Underperform)Total Votes: 159MarketBeat's community ratings are surveys of what our community members think about Sensus Healthcare and other stocks. Vote "Outperform" if you believe SRTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRTS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2019 by MarketBeat.com StaffFeatured Article: What is a front-end load?